AnalystsRyan DeschnerRyan Deschner's Stock Forecasts
AnalystsRyan Deschner
Sectors:
Industries:
Analyst Ranking
Top 17%
#826 out of 5020 analysts
Average Return
+45.76%
Win Rate
79%15 out of 19
Risk vs Reward
Poor
Good
Ryan Deschner's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Inozyme Pharma IncINZY | +270.37% | $1.08 | $4.00 | 2025-03-12 - 2025-07-01 | Buy |
Liquidia CorpLQDA | +183.15% | $9.79 | $27.72 | 2024-08-19 - 2025-08-18 | Strong Buy |
Trevi Therapeutics IncTRVI | +129.59% | $3.16 | $7.26 | 2024-08-30 - 2025-08-29 | Buy |
Liquidia CorpLQDA | +83.91% | $14.11 | $25.95 | 2024-08-16 - 2025-08-15 | Buy |
Liquidia CorpLQDA | +63.83% | $15.26 | $25.00 | 2025-05-09 - 2025-09-17 | Strong Buy |
Ryan Deschner Analyst Color
Get additional color on Ryan Deschner's coverage of popular stocks
Ryan Deschner's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Liquidia CorpLQDA | 4 | Strong Buy | $41.00 | +64.00% | Maintains | a month ago |
Trevi Therapeutics IncTRVI | 3 | Strong Buy | $27.00 | +238.35% | Maintains | a month ago |
Palvella Therapeutics IncPVLA | 1 | Buy | $54.00 | -4.54% | Initiates Coverage On | a month ago |
Ardelyx IncARDX | 2 | Buy | $12.00 | +93.86% | Maintains | a month ago |
Apellis Pharmaceuticals IncAPLS | 2 | Buy | $50.00 | +116.17% | Maintains | 2 months ago |
Viking Therapeutics IncVKTX | 1 | Strong Buy | $122.00 | +428.37% | Maintains | 2 months ago |
Tvardi Therapeutics IncTVRD | 1 | Buy | $62.00 | +58.81% | Initiates Coverage On | 2 months ago |
Inozyme Pharma IncINZY | 2 | Hold | $4.00 | 0.00% | Downgrades | 4 months ago |
Ars Pharmaceuticals IncSPRY | 3 | Strong Buy | $28.00 | +192.58% | Maintains | 8 months ago |
Omega Therapeutics IncOMGAQ | 1 | Buy | $12.00 | N/A | Initiates Coverage On | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.